...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Sao Paulo Medical Journal >Evaluation of prostate specific antigen in the prognosis of patients with advanced prostate cancer
【24h】

Evaluation of prostate specific antigen in the prognosis of patients with advanced prostate cancer

机译：前列腺特异性抗原在晚期前列腺癌患者预后中的评估

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: To evaluate the survival rate of patients with advanced prostate cancer in a univariate form, according to the preoperative and first postoperative determination of PSA levels. MATERIALS AND METHODS: From February 1987 to June 1995, 92 patients were submitted to maximum blockage androgen (subcapsular and antiandrogen orchiectomy), independent of clinical symptons shown upon admission to the Cancer Hospital. The antiandrogens (ciproterone acetate and flutamide) were administered until the patient present progression of the disease. RESULTS: The age of patients varied from 44 to 89, with a median of 70 years old. In the 6th, 36th and 60th months the global survival rate was 80%, 38% and 20%, respectively. The preoperative PSA ranged from 2 to 4017 ng/ml, with a median of 98 ng/ml (98% had PSA greater than or equal to 10 ng/ml). The first postoperative PSA ranged from 1 to 3840 ng/ml, with a median of 20 ng/ml. There was a tendency towards a better survival rate only in patients with initial PSA from 2 to 99 ng/ml (p=0.06745). The survival rate of patients at 36 months after the initial total blockage androgen, with first PSA level from 1 to 4, 5 to 49 and over 49 ng/ml was 72%, 48% and 8%, respectively (p=0.00004). In the final examination, 34 (37%) patients were considered stable and 58 (63%) had disease progression. CONCLUSION: The PSA determination performed on the 30th postoperative day is important in the evaluation of advanced prostate cancer prognosis.
机译：目的：根据术前和术后首次测定PSA水平，以单变量形式评估晚期前列腺癌患者的生存率。材料与方法：从1987年2月至1995年6月，有92例患者接受了最大程度的雄激素阻断（包膜下和抗雄激素睾丸切除术），而与进入癌症医院的临床症状无关。给予抗雄激素药物（醋酸cip曲酮和氟他米特），直到患者出现疾病进展。结果：患者年龄从44岁到89岁不等，中位年龄为70岁。在第6、36和60个月，全球生存率分别为80％，38％和20％。术前PSA为2至4017 ng / ml，中位数为98 ng / ml（98％的PSA大于或等于10 ng / ml）。术后首例PSA范围为1至3840 ng / ml，中位数为20 ng / ml。只有初始PSA从2到99 ng / ml的患者才有更好的生存率的趋势（p = 0.06745）。初次完全阻断雄激素后36个月的患者生存率分别为72％，48％和8％，首次PSA水平为1-4、5至49 ng / ml（p = 0.00004）。在最终检查中，有34名（37％）的患者被认为是稳定的，而58名（63％）的患者有疾病进展。结论：术后30天进行PSA测定对于评估晚期前列腺癌的预后具有重要意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号